Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00612105 | Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN) | PHASE2 | COMPLETED | 187 | — | — | Oct 1, 2007 | Dec 1, 2009 | May 8, 2018 | 45 | United States, South Africa |
Change from Baseline (BL) was calculated as the value of the average diary pain score for the last 7 days of the MP minus the value of the average pain score at BL (post wash-out period, including the average of the last 7 available entries prior to/including the diary pain measurement on Titration Day 0). Based on their pain experienced during the previous 24 hours, participants assessed their pain every evening at bedtime in an electronic diary by choosing the appropriate number on an 11-point Numerical Rating Scale (NRS): 0, no pain; 1 to 3, mild; 4 to 6, moderate; 7 to 10, severe pain.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Retigabine |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Retigabine | DRUG | 150mg/day up to 900mg/day |
| Placebo | DRUG | daily |
Inclusion Criteria: * Ability to provide informed consent * Male or female subjects * 18-85 years of age * PHN for more than 6 months after the healing of herpes zoster skin rash * Has a pain score at screening and randomization that qualifies Exclusion Criteria: * Other significant pain that may...